Zimmer Biomet (ZBH) Fundamental Analysis: Revenue, Earnings & Valuation

7.87 / 10

Outperform

Fundamental analysis rates ZBH as Outperform with a 7.9/10 score. Profit‑to‑market, ROE, ROA and annualized returns rank in top quartiles, indicating strong profitability. Asset‑to‑market is modestly negative and cash metrics lag, but overall financial health remains robust.

Analysis Checks(9/10)

ROA (%)

Value3.17

Score3/3

Weight16.10%

1M Return1.79%

Annualized return on equity (%)

Value5.60

Score3/3

Weight14.62%

1M Return1.64%

Profit-MV

Value0.71

Score2/3

Weight28.88%

1M Return3.26%

Cash-UP

Value0.14

Score2/3

Weight-26.34%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value3.17

Score3/3

Weight16.10%

1M Return1.79%

ROE (diluted) (%)

Value5.55

Score2/3

Weight9.35%

1M Return1.11%

Asset-MV

Value-0.55

Score2/3

Weight30.87%

1M Return3.42%

ROE (%)

Value5.60

Score3/3

Weight14.62%

1M Return1.64%

Cash-MV

Value0.32

Score1/3

Weight-22.71%

1M Return-3.56%

Net profit / Total profit (%)

Value84.87

Score3/3

Weight18.52%

1M Return2.09%

Is ZBH undervalued or overvalued?

ZBH scores 7.87/10 on fundamentals and holds a Discounted valuation at present. Backed by its 5.60% ROE, 8.57% net margin, 24.32 P/E ratio, 1.35 P/B ratio, and -20.00% earnings growth, these metrics solidify its Outperform investment rating.